I-Mab (NASDAQ:IMAB) Raised to Buy at Wall Street Zen

I-Mab (NASDAQ:IMAB - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of I-Mab in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of I-Mab in a research report on Wednesday.

I-Mab Stock Up 3.9%

Shares of NASDAQ:IMAB opened at $2.13 on Friday. The business's 50-day moving average is $1.78 and its 200 day moving average is $1.21. I-Mab has a 1 year low of $0.60 and a 1 year high of $3.08.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC acquired a new position in shares of I-Mab in the first quarter valued at about $398,000. Cantor Fitzgerald L. P. acquired a new position in shares of I-Mab in the fourth quarter valued at about $119,000. BNP Paribas Financial Markets acquired a new stake in I-Mab during the fourth quarter worth about $93,000. Millennium Management LLC grew its holdings in I-Mab by 763.1% during the fourth quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares during the period. Finally, Ground Swell Capital LLC acquired a new stake in I-Mab during the first quarter worth about $53,000. 38.38% of the stock is owned by institutional investors and hedge funds.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.